There is no top secret recipe behind the success of Taste for Hope. All that’s required is a handful of ingredients: benevolent chefs, generous sponsors, community-minded business leaders and hungry foodies working together toward the shared goal of reducing chronic homelessness. Already an Insider? Log in Get Instant Access to This Article Become an Ottawa Business Journal Insider and get immediate access to all of our Insider-only content and much more. Learn More and Become an Insider Critical Ottawa business news and analysis updated daily. Immediate access to all Insider-only content on our website. 4 issues per year of the Ottawa Business Journal magazine. Special bonus issues like the Ottawa Book of Lists. Discounted registration for OBJ’s in-person events. Click here to purchase a paywall bypass link for this article.
There is no top secret recipe behind the success of Taste for Hope. All
An Ottawa-based startup working on treatments that use the body’s immune system to target cancer, COVID-19 and other diseases has landed millions of dollars in financing to ratchet up its research efforts.
Orion Biotechnology’s new series-A round worth US$11.5 million is being led by Keiretsu Forum, a global syndicate of angel investors headquartered in San Francisco.
The new funding will help the firm expand its clinical trials of drug candidates produced by its proprietary platform that targets G-protein coupled receptors, or GPCRs, which play a key role in diseases such as cancer, HIV and acute respiratory distress syndrome (ARDS) associated with the virus that causes COVID-19.